Spots Global Cancer Trial Database for refractory acute lymphoblastic leukemia

Every month we try and update this database with for refractory acute lymphoblastic leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia	NCT03504644	B Acute Lymphob... Lymphoblasts 5 ... Recurrent Adult... Recurrent Child... Refractory Acut... T Acute Lymphob...	Laboratory Biom... Venetoclax Vincristine Lip...	18 Years -	Eastern Cooperative Oncology Group
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies	NCT05418088	Recurrent Acute... Recurrent B Acu... Recurrent B-Cel... Recurrent Chron... Recurrent High ... Recurrent Indol... Recurrent Non-H... Recurrent Trans... Refractory Acut... Refractory B Ac... Refractory B-Ce... Refractory Chro... Refractory High... Refractory Indo... Refractory Non-... Refractory Tran...	Anti-CD19/CD20/... Cyclophosphamid... Fludarabine Pho...	18 Years -	Ohio State University Comprehensive Cancer Center
Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies	NCT03241940	B Acute Lymphob... CD19 Positive Minimal Residua... Philadelphia Ch... Recurrent Adult... Recurrent Child... Refractory Acut...	Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Questionnaire A...	1 Year - 30 Years	Stanford University
A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia	NCT05761171	Recurrent Acute... Recurrent Acute... Recurrent Acute... Recurrent Acute... Recurrent Acute... Recurrent Mixed... Refractory Acut... Refractory Acut... Refractory Acut... Refractory Acut... Refractory Acut... Refractory Mixe...	Biospecimen Col... Bone Marrow Asp... Calaspargase Pe... Cytarabine Echocardiograph... Fludarabine Pho... Hydrocortisone ... Lumbar Puncture Methotrexate Multigated Acqu... Prednisolone Prednisone Revumenib Vincristine Sul...	1 Month - 6 Years	Children's Oncology Group
Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia	NCT04562792	Relapsed Pediat... Relapsed Pediat... Refractory Acut... Refractory Acut...	Daunorubicin	1 Year - 21 Years	Children's Mercy Hospital Kansas City
Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Acute Lymphoblastic Leukemia	NCT04012879	Relapsed Acute ... Refractory Acut...	CD19 CART	18 Years - 65 Years	Chinese PLA General Hospital
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia	NCT03263572	Accelerated Pha... Acute Lymphobla... BCR-ABL1 Fusion... Blast Phase Chr... Philadelphia Ch... Recurrent Acute... Refractory Acut... t(9;22)	Blinatumomab Cytarabine Methotrexate Ponatinib	18 Years -	M.D. Anderson Cancer Center
Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias	NCT04000698	Refractory Acut... Refractory Acut...	Preparative reg...	- 25 Years	Federal Research Institute of Pediatric Hematology, Oncology and Immunology
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome	NCT03670966	Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Recurrent Acute... Recurrent Acute... Refractory Acut... Refractory Acut... Recurrent Mixed... Refractory Mixe... Hematopoietic a...	Astatine At 211... Cyclophosphamid... Total-Body Irra... Peripheral Bloo... Bone Marrow Tra... Mycophenolate M... Recombinant Gra... Fludarabine Pho... Tacrolimus Bone Marrow Asp... Biospecimen Col...	18 Years - 75 Years	Fred Hutchinson Cancer Center
CART22 Alone or in Combination With huCART19 for ALL	NCT03620058	Chemotherapy Re... Refractory Acut...	CART22-65s cell... huCART19 Cells	18 Years -	University of Pennsylvania
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia	NCT03136146	Recurrent Acute... Recurrent Adult... Recurrent Burki... Recurrent Burki... Recurrent Child... Recurrent High ... Refractory Acut... Refractory Burk... Refractory Burk... Refractory High... Refractory Lymp...	Bortezomib Clofarabine Cyclophosphamid... Dexamethasone Etoposide Ofatumumab Pegfilgrastim Rituximab Vincristine Sul...	15 Years -	M.D. Anderson Cancer Center
NK Cells in Cord Blood Transplantation	NCT01619761	Accelerated Pha... Acute Biphenoty... Acute Lymphobla... Acute Myeloid L... Chronic Phase C... DS Stage II Pla... DS Stage III Pl... High Grade B-Ce... ISS Stage II Pl... ISS Stage III P... Myelodysplastic... Recurrent Acute... Recurrent Acute... Recurrent Chron... Recurrent Hodgk... Recurrent Non-H... Recurrent Small... Refractory Acut... Refractory Chro... Refractory Hodg... Refractory Non-... Refractory Smal... Secondary Acute... Therapy-Related... Therapy-Related...	Allogeneic Hema... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Lenalidomide Melphalan Mycophenolate M... Natural Killer ... Rituximab Tacrolimus Total-Body Irra... Umbilical Cord ...	- 75 Years	M.D. Anderson Cancer Center
Study of Anti-CD22 CAR-T Cells Treating Leukemia Children	NCT04340167	Acute Lymphobla... Acute Lymphobla... Refractory Acut...	Autologous huma...	0 Years - 18 Years	Beijing Boren Hospital
Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies	NCT03241940	B Acute Lymphob... CD19 Positive Minimal Residua... Philadelphia Ch... Recurrent Adult... Recurrent Child... Refractory Acut...	Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Questionnaire A...	1 Year - 30 Years	Stanford University
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia	NCT03263572	Accelerated Pha... Acute Lymphobla... BCR-ABL1 Fusion... Blast Phase Chr... Philadelphia Ch... Recurrent Acute... Refractory Acut... t(9;22)	Blinatumomab Cytarabine Methotrexate Ponatinib	18 Years -	M.D. Anderson Cancer Center
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD	NCT02220985	Accelerated Pha... Acute Biphenoty... Acute Leukemia ... Acute Undiffere... Allogeneic Hema... Blast Phase Chr... Blastic Plasmac... Childhood Acute... Childhood Acute... Donor Lymphoblastic L... Myelodysplastic... Myelodysplastic... Myelodysplastic... Recurrent Acute... Recurrent Acute... Recurrent Child... Recurrent Child... Recurrent Chron... Refractory Acut... Refractory Acut... Acute Lymphobla... Acute Myeloid L...	Allogeneic Hema... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Methotrexate Mycophenolate M... Peripheral Bloo... Peripheral Bloo... Tacrolimus Thiotepa Total-Body Irra...	- 60 Years	Fred Hutchinson Cancer Center
Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia	NCT03576547	Blast Phase Chr... Philadelphia Ch... Recurrent Acute... Recurrent Chron... Refractory Acut... Refractory Chro... t(9;22)	Dexamethasone Ponatinib Hydro... Rituximab Venetoclax	18 Years -	M.D. Anderson Cancer Center
Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL	NCT03349281	Refractory Acut... Relapsed Acute ...	Pevonedistat Vincristine Dexamethasone PEG-asparaginas... Doxorubicin Cytarabine Methotrexate Hydrocortisone	16 Years - 39 Years	University of Miami
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma	NCT03096782	Accelerated Pha... Acute Biphenoty... Acute Leukemia Acute Lymphobla... Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Chemotherapy-Re... Chronic Lymphoc... Chronic Myeloge... Chronic Myelomo... Hodgkin Lymphom... Langerhans Cell... Minimal Residua... Myelodysplastic... Myelodysplastic... Non-Hodgkin Lym... Recurrent Hodgk... Refractory Acut... Refractory Myel... Small Lymphocyt... Therapy-Related...	Anti-Thymocyte ... Busulfan Clofarabine Cyclophosphamid... Filgrastim-sndz Fludarabine Melphalan Mycophenolate M... Rituximab Tacrolimus Total-Body Irra... Umbilical Cord ...	12 Years - 65 Years	M.D. Anderson Cancer Center
Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia	NCT03504644	B Acute Lymphob... Lymphoblasts 5 ... Recurrent Adult... Recurrent Child... Refractory Acut... T Acute Lymphob...	Laboratory Biom... Venetoclax Vincristine Lip...	18 Years -	Eastern Cooperative Oncology Group
Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias	NCT04000698	Refractory Acut... Refractory Acut...	Preparative reg...	- 25 Years	Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia	NCT03132454	Recurrent Acute... Recurrent Acute... Refractory Acut... Refractory Acut...	Decitabine Dexamethasone Palbociclib Sorafenib	15 Years -	M.D. Anderson Cancer Center
A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents	NCT05334823	Acute Lymphobla... Relapsed Pediat... Refractory Acut...	pCAR-19B cells	3 Years - 21 Years	Chongqing Precision Biotech Co., Ltd
Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia	NCT03576547	Blast Phase Chr... Philadelphia Ch... Recurrent Acute... Recurrent Chron... Refractory Acut... Refractory Chro... t(9;22)	Dexamethasone Ponatinib Hydro... Rituximab Venetoclax	18 Years -	M.D. Anderson Cancer Center
Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia	NCT03132454	Recurrent Acute... Recurrent Acute... Refractory Acut... Refractory Acut...	Decitabine Dexamethasone Palbociclib Sorafenib	15 Years -	M.D. Anderson Cancer Center
Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL	NCT04888442	Acute Lymphobla... Refractory Acut...	pCAR-19B cells	22 Years - 70 Years	Chongqing Precision Biotech Co., Ltd
Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia	NCT04562792	Relapsed Pediat... Relapsed Pediat... Refractory Acut... Refractory Acut...	Daunorubicin	1 Year - 21 Years	Children's Mercy Hospital Kansas City
A Study of Children With Refractory or Relapsed ALL	NCT00187083	Acute Lymphobla...	Topotecan, dexa... E. coli Asparag... erwinia asparag... fludarabine, me... idarubicin, eto... chemotherapy, i...	- 18 Years	St. Jude Children's Research Hospital
Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia	NCT03512405	CD19 Positive Philadelphia Ch... Recurrent Acute... Refractory Acut...	Blinatumomab Laboratory Biom... Pembrolizumab	18 Years -	City of Hope Medical Center
CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia	NCT06316856	T-Cell Acute Ly... Acute Lymphobla... Refractory Acut...	Autologous CD5 ... Previous stem-c... Newly matched d...	1 Year - 70 Years	Beijing GoBroad Hospital
Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL	NCT04888442	Acute Lymphobla... Refractory Acut...	pCAR-19B cells	22 Years - 70 Years	Chongqing Precision Biotech Co., Ltd
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia	NCT04752163	Hematopoietic a... Recurrent Acute... Recurrent Acute... Recurrent Chron... Recurrent Myelo... Refractory Acut... Refractory Acut... Refractory Chro... Refractory Myel...	DS-1594b Azacitidine Cyclophosphamid... Cytarabine Dexamethasone Filgrastim Leucovorin Mesna Methotrexate Posaconazole Prednisone Rituximab Venetoclax Vincristine Voriconazole	18 Years -	M.D. Anderson Cancer Center
Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia	NCT03094611	CD22 Positive Recurrent Acute... Refractory Acut...	Inotuzumab Ozog...	12 Years -	M.D. Anderson Cancer Center
Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma	NCT01658007	Relapsed Lympho... Recurrent Adult... Refractory Acut... Refractory Lymp...	Sirolimus	- 30 Years	Children's Hospital Medical Center, Cincinnati
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia	NCT03128034	Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Recurrent Acute... Refractory Acut... Recurrent Acute... Recurrent Mixed... Refractory Acut... Refractory Mixe... Mixed Phenotype...	Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Pharmacological... Pretargeted Rad... Total-Body Irra...	18 Years - 75 Years	Fred Hutchinson Cancer Center
Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax	NCT05192889	Refractory Acut... Relapsed Acute ...	Venetoclax Navitoclax Dexamethasone Vincristine Calaspargase Pe... Dasatinib Cytarabine Blinatumomab Methotrexate Mercaptopurine Cyclophosphamid... Etoposide Leucovorin Intrathecal Tri... Pegaspargase Erwinia asparag... Radiation	4 Years - 30 Years	St. Jude Children's Research Hospital
Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL	NCT03349281	Refractory Acut... Relapsed Acute ...	Pevonedistat Vincristine Dexamethasone PEG-asparaginas... Doxorubicin Cytarabine Methotrexate Hydrocortisone	16 Years - 39 Years	University of Miami
CART22 Alone or in Combination With huCART19 for ALL	NCT03620058	Chemotherapy Re... Refractory Acut...	CART22-65s cell... huCART19 Cells	18 Years -	University of Pennsylvania
Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia	NCT03575325	Lymphoid Leukem... Acute Lymphobla... Refractory Acut... Relapsed Acute ...	CPX-351	18 Years -	H. Lee Moffitt Cancer Center and Research Institute
A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia	NCT05761171	Recurrent Acute... Recurrent Acute... Recurrent Acute... Recurrent Acute... Recurrent Acute... Recurrent Mixed... Refractory Acut... Refractory Acut... Refractory Acut... Refractory Acut... Refractory Acut... Refractory Mixe...	Biospecimen Col... Bone Marrow Asp... Calaspargase Pe... Cytarabine Echocardiograph... Fludarabine Pho... Hydrocortisone ... Lumbar Puncture Methotrexate Multigated Acqu... Prednisolone Prednisone Revumenib Vincristine Sul...	1 Month - 6 Years	Children's Oncology Group
Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax	NCT05192889	Refractory Acut... Relapsed Acute ...	Venetoclax Navitoclax Dexamethasone Vincristine Calaspargase Pe... Dasatinib Cytarabine Blinatumomab Methotrexate Mercaptopurine Cyclophosphamid... Etoposide Leucovorin Intrathecal Tri... Pegaspargase Erwinia asparag... Radiation	4 Years - 30 Years	St. Jude Children's Research Hospital
Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children	NCT04325841	Acute Lymphobla... Acute Lymphobla... Refractory Acut...	Murine autologo...	0 Years - 18 Years	Beijing Boren Hospital
CART22 Alone or in Combination With huCART19 for ALL	NCT03620058	Chemotherapy Re... Refractory Acut...	CART22-65s cell... huCART19 Cells	18 Years -	University of Pennsylvania
Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL	NCT03349281	Refractory Acut... Relapsed Acute ...	Pevonedistat Vincristine Dexamethasone PEG-asparaginas... Doxorubicin Cytarabine Methotrexate Hydrocortisone	16 Years - 39 Years	University of Miami
Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia	NCT03575325	Lymphoid Leukem... Acute Lymphobla... Refractory Acut... Relapsed Acute ...	CPX-351	18 Years -	H. Lee Moffitt Cancer Center and Research Institute
Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Acute Lymphoblastic Leukemia	NCT04012879	Relapsed Acute ... Refractory Acut...	CD19 CART	18 Years - 65 Years	Chinese PLA General Hospital
High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia	NCT02551718	Recurrent Acute... Recurrent Acute... Recurrent Acute... Refractory Acut... Refractory Acut... Refractory Acut...	Chemosensitivit... Cytology Specim... Gene Expression... Genetic Variati... In Vitro Sensit...	3 Years -	University of Washington
Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Acute Lymphoblastic Leukemia/Lymphoma	NCT06316427	T-cell Acute Ly... Acute Lymphobla... Refractory Acut...	Autologous CD7 ... Prior-HSCT dono... New donor-deriv...	1 Year - 70 Years	Beijing GoBroad Hospital

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: